Top 10, a best-selling oral drug, has been evaluated for consistency among four varieties! Which enterprises lead the way?

At present, there are 41 product specifications in the published 4 batches of drugs that have passed the consistency evaluation According to statistics, 289 kinds of essential drugs involve 17740 approvals, 1817 domestic enterprises and 42 import enterprises According to the regulations, if there are more than three manufacturers that have passed the consistency evaluation for the same kind of drugs, no more varieties that have failed the consistency evaluation will be selected in terms of centralized purchase of drugs So whether we can speed up to the top three is of great significance to seize the market The consistency evaluation of generic drugs starts from oral drugs At present, domestic pharmaceutical companies are very fierce in the competition for varieties with large market sales To get the priority of the consistency evaluation ticket means that they can enjoy a variety of policy dividends, and then quickly seize the market and expand the market scale The author combed the domestic best-selling oral heavyweight products In top 10, four kinds of oral preparations have been evaluated for consistency by enterprises, mainly including tablets, capsules, soft capsules, drop pills, oral powder, granules, pills, etc According to the data statistics of domestic sample hospitals, the sales volume of oral preparations of domestic sample hospitals in 2017 was 67.4 billion yuan, of which the top 10 oral preparations accounted for 13.42 billion yuan, accounting for 20% of the overall oral preparations Market It is estimated that the market scale of the top 10 oral preparations is about 70 billion yuan In 2017, the top 10 sales volume of the best-selling oral preparations in the domestic sample hospitals were: clopidogrel 2.39 billion yuan, atorvastatin 2.21 billion yuan, entecavir 2.0 billion yuan, tegio 1.17 billion yuan, rosuvastatin 1.1 billion yuan, acarbose 1.09 billion yuan, rabeprazole 1.06 billion yuan, tacrolimus 0.97 billion yuan, capecitabine 0.94 billion yuan, and metoclopramide 0.77 billion yuan Among the top 10 best-selling oral drugs, the enterprises and products that have passed the consistency evaluation of generic drugs include: clopidogrel of Shenzhen xinlitai Pharmaceutical Co., Ltd., atorvastatin of Beijing Jialin Pharmaceutical Co., Ltd., entecavir of Zhengda Tianqing Pharmaceutical Co., Ltd., Jiangxi Qingfeng Pharmaceutical Co., Ltd., Nanjing Zhengda Tianqing Pharmaceutical Co., Ltd and ruishuvastatin of Zhejiang Jingxin Pharmaceutical Co., Ltd Clopidogrel: "leader" xinlitai takes the lead in one step Two specifications of clopidogrel bisulfate, 75mg and 25mg, have passed the consistency evaluation Clopidogrel was developed by Sanofi and its trade name is Plavix It entered China in August 2001 At present, 3 enterprises have been approved to produce clopidogrel in China, including 1 import enterprise and 2 local enterprises According to the data statistics of domestic sample hospitals, in 2017, the amount of clopidogrel used reached 2.39 billion yuan, and the actual market scale exceeded 10 billion yuan Among them, Plavix of Sanofi accounts for 59.2%, Taijia of Shenzhen xinlitai accounts for 30.1%, and Shuai of Lepu pharmaceutical accounts for 10.6% This variety was first imitated by xinlitai pharmaceutical The market share of cimetil clopidogrel in the local enterprises is the largest This time, it is the first to pass the consistency evaluation of generic drugs, which will undoubtedly help it to seize the share of original research products Atorvastatin: Jialin Pharmaceutical Co., Ltd has first passed the customs clearance of Beijing Jialin Pharmaceutical Co., Ltd the two products of atorvastatin calcium tablets, 10mg and 20mg, have passed the consistency evaluation This product is developed by Pfizer, and the trade name is Lipitor In 1999, Arle, developed by Beijing Jialin Pharmaceutical Co., Ltd., was first listed in China, and then, huiruiputuo of the United States obtained administrative protection in China, which was sold by Dalian Pfizer Pharmaceutical Co., Ltd in China The main dosage forms of the product are tablets and capsules At present, 6 enterprises have been approved for production, including 2 import enterprises and 4 local enterprises According to the data statistics of domestic sample hospitals, atorvastatin has maintained a high-speed growth trend from 2012 to 2017 In 2012, the amount of drug use was 1.57 billion yuan, and in 2017, the amount of drug use reached 2.39 billion yuan In the domestic sample hospital market, in 2017, Pfizer's Lipitor accounted for 73.4%, Beijing Jialin pharmaceutical's Aloe accounted for 17.4%, Henan Tianfang pharmaceutical's Youjia accounted for 5.8%, Guangdong Zhejiang new east port's yuliping accounted for 1.4%, Guangdong encyclopedia's Jingshu accounted for 1.0%, and sloveniaco's shanletin accounted for 0.7% Pfizer's Lipitor has always been a monopoly Rosuvastatin: the share of the original research drug is in a downward trend The 10 mg standard of Tianqing and the 10 mg and 5 mg calcium tablets of Zhejiang Jingxin Pharmaceutical Co., Ltd have passed the consistency evaluation This product is developed by AstraZeneca, and its trade name is Keding Because of its advantages in efficacy, it has surpassed atorvastatin and become the first heavyweight product of statins In April 2007, rosuvastatin of AstraZeneca was approved to be listed in China With the enhancement of domestic enterprises' awareness of parody and the rapid layout of local enterprises, many enterprises' products have entered the market The main dosage forms are tablets, capsules and dispersible tablets At present, 7 enterprises have been approved for production, including 1 import enterprise and 6 local enterprises According to the data statistics of domestic sample hospitals, rosuvastatin has maintained a rapid growth trend from 2012 to 2017 In 2012, the amount of drug use was 370 million yuan, and in 2017, the amount of drug use reached 1.1 billion yuan The market competition pattern of this product is as follows: AstraZeneca's products account for 67.4%, lunanbeite's products account for 17.0%, Zhejiang Jingxin pharmaceutical's products account for 6.9%, and other enterprises' products account for 8.5% Rosuvastatin market is dominated by AstraZeneca, but its market share has declined in recent years Entecavir: the advantage of Zhengda Tianqing is obvious Entecavir dispersible tablets of 0.5mg standard of Zhengda Tianqing Pharmaceutical Co., Ltd have passed the consistency evaluation; entecavir dispersible tablets and entecavir capsules of 0.5mg standard of Jiangxi Qingfeng Pharmaceutical Co., Ltd have passed the consistency evaluation Entecavir was developed by Bristol Myers Squibb and was approved by the FDA in March 2005 The product name is bolutin In November 2005, entecavir of Shanghai Squibb was imported Since the product entered the Chinese market, it soon became the first-line drug of choice for hepatitis B in 2009, it rapidly replaced adefovir, an early nucleoside drug, and has been ranked first The main dosage forms are ordinary tablets, capsules and dispersible tablets At present, 10 enterprises of entecavir have been approved for production, including 1 import enterprise and 9 local enterprises According to the data of domestic sample hospitals, the amount of entecavir in 2017 has reached 1.995 billion yuan The market competition pattern is as follows: the market share of Runzhong, GANZE and Tianding in Zhengda Tianqing Pharmaceutical Co., Ltd is 44.2%, that of Shanghai Squibb Pharmaceutical Co., Ltd in China and the United States is 39.8%, and that of eight other local enterprises is 16.0% At present, Zhengda Tianqing Pharmaceutical Co., Ltd has three dosage forms of entecavir dispersible tablets, capsules and entecavir maleate tablets, with obvious advantages Before 2010, a product of Bristol Myers Squibb monopolized the market Since then, domestic enterprises have broken the monopoly pattern In recent years, the market competition has been extremely fierce.